Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (7522)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 11.683
4.

Respuesta inmune humoral inducida por la vacuna influenza en niños con diagnóstico de leucemia linfoblástica aguda/ Humoral immune response induced by influenza vaccine in children with acute lymphoblastic leukemia

Autor(es): Cerda, Carolina; Martínez-Valdebenito, Constanza; Barriga, Francisco; Contreras, Marcela; Vidal, Marcela; Moreno, Rosa; Claverie, Ximena; Contreras, Paola; Huenuman, Lesly; García, Tamara; Rathnasighe, Raveen; Medina, Rafael; Ferrés, Marcela; Le Corre, Nicole
Fonte: Rev. chil. infectol;37(2): 138-146, abr. 2020. tab, graf
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 1126100
Resumo: Resumen Introducción: Los pacientes con leucemia linfoblástica aguda (LLA) tienen alto riesgo de influenza grave y la vacunación es altamente recomendada. La inmunogenicidad y efectividad de la vacuna es menor comparada a los sujetos sanos. Objetivo: Evaluar la respuesta inmune inducida por vacuna anti-influenza en niños con LLA y observar su efectividad. Métodos: Se reclutaron niños con LLA en terapia de mantención y niños sanos. Se tomaron muestras de sangre el día de la vacun (mais)
6.

Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety.

Autor(es): Chen, Yong-Chao; Zhou, Jia-Hao; Tian, Jia-Ming; Li, Bai-Hui; Liu, Li-Hui; Wei, Ke
Fonte: Hum Vaccin Immunother;16(3): 612-622, 2020 Mar 03.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31567058
Resumo: Adjuvanted-influenza vaccination is an efficient method for enhancing the immunogenicity of influenza split-virus vaccines for preventing influenza. However, the medical community's understanding of its performance in patients infected with HIV remains limited. To identify the advantages, we conducted a systematic review and meta-analysis with randomized controlled trials (RCTs) and cohort and case-control studies that have the immunogenicity and safety of influenza vaccines in patients inf (mais)
7.

Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016-2017 season in Beijing, China.

Autor(es): Zhang, Li; van der Hoek, Wim; Krafft, Thomas; Pilot, Eva; Asten, Liselotte van; Lin, Ge; Wu, Shuangsheng; Duan, Wei; Yang, Peng; Wang, Quanyi
Fonte: Hum Vaccin Immunother;16(4): 816-822, 2020 Apr 02.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31596661
Resumo: Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016-2017 influenza season.Methods: The VE of 2016-2017 TIV against laboratory-confirmed influenza (mais)
8.

Factors associated with adverse outcomes during influenza outbreaks in aged care facilities.

Autor(es): Tennant, Elaine; Fletcher, Stephanie; Kakar, Sheena; Najjar, Zeina; Lord, Heidi; Clark, Penelope; Gupta, Leena
Fonte: Aust N Z J Public Health;44(1): 65-72, 2020 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31617654
Resumo: OBJECTIVE: To explore factors associated with adverse outcomes during influenza outbreaks in residential aged care facilities. METHODS: A retrospective cohort study of all outbreaks reported to three Sydney metropolitan Public Health Units during 2017. RESULTS: A total of 123 outbreaks affected 1,787 residents and 543 staff. Early notification to a Public Health Unit was associated with shorter outbreak duration (p<0.001; B=0.674). Resident attack rates and resident mortality rates were low (mais)
9.

Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection.

Autor(es): Mandon, Elodie Desuzinges; Pizzorno, Andrés; Traversier, Aurélien; Champagne, Anne; Hamelin, Marie Eve; Lina, Bruno; Boivin, Guy; Dejean, Emmanuel; Rosa-Calatrava, Manuel; Jawhari, Anass
Fonte: Vaccine;38(2): 278-287, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31630939
Resumo: Influenza A viruses cause major morbidity and represent a severe global health problem. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100, which implies certain limitations. Here, we report the use of the novel calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation. We confirmed that CALX133ACE-based split HA antigens are f (mais)
10.

Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England.

Autor(es): Pebody, R G; Zhao, H; Whitaker, H J; Ellis, J; Donati, M; Zambon, M; Andrews, N
Fonte: Vaccine;38(2): 158-164, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31648914
Resumo: 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged (mais)
11.

Protection provided by influenza vaccine against influenza-related hospitalisation in ≥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19.

Autor(es): Pebody, Richard; Whitaker, Heather; Zhao, Hongxin; Andrews, Nick; Ellis, Joanna; Donati, Matthew; Zambon, Maria
Fonte: Vaccine;38(2): 173-179, 2020 Jan 10.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31653528
Resumo: 2018/19 was the first season of introduction in England of a newly licensed adjuvanted influenza vaccine (aTIV) for adults 65 years or older, who were previously offered standard-dose, non-adjuvanted vaccine, achieving uptake levels >70%, often with poor effectiveness. This paper presents the end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza hospitalisation in this population. A frequency-matched test negative case control approach was used to es (mais)
12.

Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant.

Autor(es): Ryan, Anne L; Wadia, Ushma D; Jacoby, Peter; Cheung, Laurence C; Kerr, Fiona; Fraser, Chris; Tapp, Heather; Mechinaud, Francoise; Carolan, Louise A; Laurie, Karen L; Barr, Ian G; Blyth, Christopher C; Gottardo, Nicholas G; Richmond, Peter C; Kotecha, Rishi S
Fonte: Bone Marrow Transplant;55(4): 773-779, 2020 Apr.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31659236
Resumo: Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibitio (mais)
Resultados  1-12 de 11.683